Connect Biopharma Holdings Stock Buy Hold or Sell Recommendation

CNTB Stock  USD 1.61  0.28  21.05%   
Given the investment horizon of 90 days and your bold attitude towards risk, our recommendation regarding Connect Biopharma Holdings is 'Strong Sell'. Macroaxis provides Connect Biopharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CNTB positions. The advice algorithm takes into account all of Connect Biopharma's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Connect Biopharma's buy or sell advice are summarized below:
Real Value
2.61
Target Price
6
Hype Value
1.54
Market Value
1.61
Naive Value
1.64
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Connect Biopharma Holdings given historical horizon and risk tolerance towards Connect Biopharma. When Macroaxis issues a 'buy' or 'sell' recommendation for Connect Biopharma Holdings, the advice is generated through an automated system that utilizes algorithms and statistical models.
  
Check out Connect Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
In addition, we conduct extensive research on individual companies such as Connect and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Connect Biopharma Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

Execute Connect Biopharma Buy or Sell Advice

The Connect recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Connect Biopharma Holdings. Macroaxis does not own or have any residual interests in Connect Biopharma Holdings or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Connect Biopharma's advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Connect BiopharmaBuy Connect Biopharma
Strong Sell

Market Performance

OKDetails

Volatility

DangerousDetails

Hype Condition

Over hypedDetails

Current Valuation

UndervaluedDetails

Odds Of Distress

LowDetails

Economic Sensitivity

Follows the market closelyDetails

Investor Sentiment

ImpartialDetails

Analyst Consensus

Strong BuyDetails

Financial Strenth (F Score)

PoorDetails

Financial Leverage

InapplicableDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails
For the selected time horizon Connect Biopharma Holdings has a Mean Deviation of 5.37, Semi Deviation of 4.99, Standard Deviation of 7.09, Variance of 50.22, Downside Variance of 32.73 and Semi Variance of 24.91
We provide trade advice to complement the prevailing expert consensus on Connect Biopharma. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Connect Biopharma is not overpriced, please confirm all Connect Biopharma fundamentals, including its net income, short ratio, working capital, as well as the relationship between the debt to equity and beta . Please also double-check Connect Biopharma Holdings price to book to validate your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.

Connect Biopharma Trading Alerts and Improvement Suggestions

Connect Biopharma is way too risky over 90 days horizon
Connect Biopharma may become a speculative penny stock
Connect Biopharma appears to be risky and price may revert if volatility continues
Net Loss for the year was (795.02 M) with profit before overhead, payroll, taxes, and interest of 0.
Connect Biopharma Holdings currently holds about 1.28 B in cash with (679.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 23.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Connect Biopharma has a poor financial position based on the latest SEC disclosures
Roughly 41.0% of the company shares are held by company insiders
Latest headline from finance.yahoo.com: Connect Biopharma to Participate in H.C. Wainwright 2 Annual Autoimmune Inflammatory Disease Virtual Conference

Connect Biopharma current analysts advice

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Connect analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Connect analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.

Connect Biopharma Returns Distribution Density

The distribution of Connect Biopharma's historical returns is an attempt to chart the uncertainty of Connect Biopharma's future price movements. The chart of the probability distribution of Connect Biopharma daily returns describes the distribution of returns around its average expected value. We use Connect Biopharma Holdings price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Connect Biopharma returns is essential to provide solid investment advice for Connect Biopharma.
Mean Return
0.92
Value At Risk
-9.29
Potential Upside
14.81
Standard Deviation
7.09
   Return Density   
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Connect Biopharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Connect Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Connect Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Connect Biopharma Holdings backward and forwards among themselves. Connect Biopharma's institutional investor refers to the entity that pools money to purchase Connect Biopharma's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Royal Bank Of Canada2023-12-31
449
Jpmorgan Chase & Co2023-12-31
121
Qube Research & Technologies2023-12-31
46.0
Fmr Inc2023-12-31
23.0
Susquehanna International Group, Llp2023-09-30
0.0
Ikarian Capital, Llc2023-09-30
0.0
Morgan Stanley - Brokerage Accounts2023-12-31
0.0
Kynam Capital Management, Lp2023-12-31
0.0
Adage Capital Partners Gp Llc2023-12-31
0.0
Ra Capital Management, Llc2023-12-31
3.1 M
Bml Capital Management Llc2023-12-31
2.1 M
Note, although Connect Biopharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Connect Biopharma Cash Flow Accounts

201920202021202220232024 (projected)
Investments(2.3M)18.2M13.5M(571.3M)(514.2M)(488.5M)
Change In Cash(92.6M)701.1M696.8M(1.2B)(1.0B)(988.9M)
Depreciation790K1.4M4.1M6.9M8.0M8.4M
Capital Expenditures1.1M15.3M47.5M29.3M33.7M20.8M
Net Income(168.6M)(779.2M)(1.3B)(795.0M)(715.5M)(751.3M)
End Period Cash Flow309.0M1.0B1.7B550.3M632.8M875.1M

Connect Biopharma Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Connect Biopharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Connect Biopharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Connect stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over NYSE Composite
0.81
β
Beta against NYSE Composite0.82
σ
Overall volatility
7.51
Ir
Information ratio 0.11

Connect Biopharma Volatility Alert

Connect Biopharma Holdings is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Connect Biopharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Connect Biopharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.

Connect Biopharma Fundamentals Vs Peers

Comparing Connect Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Connect Biopharma's direct or indirect competition across all of the common fundamentals between Connect Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Connect Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Connect Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Connect Biopharma by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Connect Biopharma to competition
FundamentalsConnect BiopharmaPeer Average
Return On Equity-0.52-0.31
Return On Asset-0.29-0.14
Current Valuation(59.07 M)16.62 B
Shares Outstanding55.07 M571.82 M
Shares Owned By Insiders41.28 %10.09 %
Shares Owned By Institutions44.03 %39.21 %
Number Of Shares Shorted107.35 K4.71 M
Price To Book0.56 X9.51 X
EBITDA(762.07 M)3.9 B
Net Income(795.02 M)570.98 M
Cash And Equivalents1.28 B2.7 B
Cash Per Share23.26 X5.01 X
Total Debt3 M5.32 B
Debt To Equity0 %48.70 %
Current Ratio9.58 X2.16 X
Book Value Per Share16.88 X1.93 K
Cash Flow From Operations(679.66 M)971.22 M
Short Ratio0.65 X4.00 X
Earnings Per Share(1.55) X3.12 X
Target Price6.49
Number Of Employees10018.84 K
Beta-0.73-0.15
Market Capitalization88.67 M19.03 B
Total Asset1.21 B29.47 B
Retained Earnings(3.18 B)9.33 B
Working Capital976.12 M1.48 B
Z Score12.978.72
Net Asset1.21 B

Connect Biopharma Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Connect . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About Connect Biopharma Buy or Sell Advice

When is the right time to buy or sell Connect Biopharma Holdings? Buying financial instruments such as Connect Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
 2021 2022 2023 2024 (projected)
Total Current Liabilities114.7M108.8M125.1M64.9M
Other Current Liabilities32.8M24.4M28.0M16.3M

Use Investing Ideas to Build Portfolios

In addition to having Connect Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Asset Allocation ETFs Thematic Idea Now

Asset Allocation ETFs
Asset Allocation ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Asset Allocation ETFs theme has 135 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Asset Allocation ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Connect Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Connect Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Connect Biopharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Connect Biopharma Holdings Stock:
Check out Connect Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for Connect Stock analysis

When running Connect Biopharma's price analysis, check to measure Connect Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Connect Biopharma is operating at the current time. Most of Connect Biopharma's value examination focuses on studying past and present price action to predict the probability of Connect Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Connect Biopharma's price. Additionally, you may evaluate how the addition of Connect Biopharma to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Global Correlations
Find global opportunities by holding instruments from different markets
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Is Connect Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.55)
Return On Assets
(0.29)
Return On Equity
(0.52)
The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Connect Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Connect Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.